The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Kite Pharma
Los Angeles, United States
B
51-100 Employees
2009
Key takeaway
Kite Pharma is dedicated to developing innovative cell therapies, including CAR-T cell therapy, which involves engineering a patient's own immune cells to specifically target and attack cancer. Their focus on research and development, bolstered by strategic partnerships, enhances their ability to transform cancer treatment and improve patient outcomes.
Reference
Core business
Transformational Cancer Treatment | Kite Pharma
Learn about Kite’s mission to change the way cancer is treated with cell therapy – the use of genetically modified immune cells programmed to target tumors.
Catamaran Bio
Cambridge, United States
B
11-50 Employees
2020
Key takeaway
The company, Catamaran Bio, is focused on developing innovative CAR-NK cell therapies that enhance the cancer-fighting potential of Natural Killer cells. Their TAILWIND® platform integrates advanced technologies to create transformative, off-the-shelf treatments for solid tumors and other cancers, aiming to significantly improve patient outcomes.
Reference
Core business
Home - Catamaran Bio
Catamaran harnesses the natural cancer-fighting properties of NK cells, the power of synthetic biology and innovative non-viral cell engineering to create novel CAR-NK cell therapies
Atara Biotherapeutics
South San Francisco, United States
B
251-500 Employees
2012
Key takeaway
Atara Biotherapeutics is focused on developing off-the-shelf, allogeneic T-cell immunotherapies, positioning itself as a leader in the CAR-T cell therapy space. With a commitment to harnessing the immune system's power, the company is advancing innovative treatments for cancer and other diseases.
Reference
Core business
Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Caribou Biosciences
Berkeley, United States
B
101-250 Employees
2011
Key takeaway
Caribou Biosciences is advancing clinical-stage allogeneic CAR-T cell therapies aimed at treating hematologic malignancies. Their innovative platform includes multiple CAR-T therapies designed to enhance efficacy and reduce immune rejection, addressing significant unmet needs in cancer treatment.
Reference
Product
CAR-T cell therapy platform | Caribou Biosciences
Triumvira Immunologics
Austin, United States
B
11-50 Employees
2015
Key takeaway
The company is developing innovative TAC-based therapeutic candidates, which may align with advances in CAR-T cell therapy, emphasizing their commitment to enhancing the body's defenses against cancer.
Reference
Core business
Home - Triumvira Immunologics | Car-T, TCR, TAC Therapies and Immunotherapy
Angeles Therapeutics Inc.
Los Angeles, United States
B
1-10 Employees
2018
Key takeaway
Angeles Therapeutics specializes in advanced cell and immune therapies, including Chimeric Antigen Receptor T (CAR-T) cell therapy, which is relevant for treating various cancers such as prostate, lung, breast, melanoma, kidney, GI cancers, lymphoma, and leukemia.
Reference
Core business
About | Angeles Therapeutics
Chimeric antigen receptor (CAR)-T cells, Chimeric antigen receptor (CAR)-NK cells, Synthetic Immune Receptor (SIR) Cell Therapy, CAR-T, CAR-NK, Prostate cancer, Lung cancer, Breast cancer, Melanoma, Kidney cancer, GI cancers, Lymphoma, Leukemia, Matador Assay, Topanga Assay, Biotechnology
Carisma Therapeutics
Philadelphia, United States
B
11-50 Employees
2016
Key takeaway
Carisma Therapeutics is pioneering the development of CAR-Macrophages, an innovative approach to immunotherapy that leverages engineered immune cells to target and attack tumors. Their emerging pipeline of oncology CAR-Macrophages positions them at the forefront of creating transformative cellular therapies for cancer treatment.
Reference
Product
CAR-Macrophage Technology | Cell Therapy | Carisma Therapeutics
Pioneering development of CAR-Macrophages, Carisma Therapeutics offers a disruptive approach to immunotherapy, giving patients hope in the fight against cancer.
Luminary Therapeutics Inc
Minneapolis, United States
B
1-10 Employees
2019
Key takeaway
Luminary Therapeutics is dedicated to overcoming the challenges of CAR-T cell therapy, particularly in manufacturing and cost. Their unique allogenic platform, Gamma 2.0+, enhances the production process and aims to establish new standards of care for B-Cell malignancies and related autoimmune diseases.
Reference
Product
Platform - Luminary Therapeutics
Luminary is keenly focused on overcoming the key challenges facing the CAR T industry namely solid tumor resistance, manufacturing hurdles, and antigen escape. Luminary has a novel one-of-a-kind allogeneic T cell manufacturing platform. Luminary's allogeneic solution is built on a manufacturing platform called Gamma 2.0+. This allogeneic manufacturing platform has three components, gamma delta 1 and gamma delta 2 T cells are combined in the final therapeutic product, a non-viral gene modification process, and an immune cloaking capability.
DiaCarta
Hayward, United States
B
11-50 Employees
2011
Key takeaway
DiaCarta is focused on enhancing cancer patient care through innovative solutions, including their Personalized CAR-T Immunotherapy Platform. This commitment to precision diagnostics and patient-centric operations underscores their role in advancing treatment options for cancer patients.
Reference
Service
CAR-T Immunotherapy | DiaCarta, Inc.
Tactiva Therapeutics
Buffalo, United States
B
1-10 Employees
2016
Key takeaway
Tactiva Therapeutics is advancing cancer treatment through its innovative adoptive T cell therapy (ACT) strategies, which involve reprogramming patients' own T cells to effectively target and destroy cancer cells. Their dual T cell receptor approach enhances the immune response, providing a robust and sustained attack on tumors.
Reference
Core business
Tactiva Therapeutics | Innovative Cancer Immunotherapy
Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.
Technologies which have been searched by others and may be interesting for you:
When exploring the CAR-T cell therapy industry in the United States, several critical factors come into play. Regulatory considerations are paramount, as therapies must undergo rigorous evaluation by the FDA, including clinical trials to ensure safety and efficacy. This process can be lengthy and costly, impacting the pace of innovation and market entry. Additionally, understanding reimbursement policies is crucial, as insurance coverage can significantly influence patient access and market dynamics. The competitive landscape is evolving, with established pharmaceutical companies and biotech startups vying for market share. This competition fosters innovation but also presents challenges in differentiation and scalability. Environmental concerns related to the production of biologics, such as waste management and carbon footprint, are gaining attention and may affect operational practices and regulatory compliance. Opportunities abound in expanding indications for CAR-T therapies, particularly in treating various cancers and autoimmune diseases. Furthermore, advancements in technology, such as gene editing and personalized medicine, are driving growth in this sector. The global market relevance of CAR-T therapy is notable, as international collaborations and research initiatives can enhance development and distribution capabilities. Overall, potential investors and stakeholders should remain informed about these factors to navigate the complexities of the CAR-T cell therapy landscape effectively.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 3620 |
| Amount of suitable service providers | 2982 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2009 |
| Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Biotechnology, Other, IT, Software and Services, Healthcare, Medical
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
